Trunk Fat Linked to Insulin Resistance
Posted on: Monday, 20 August 2007, 15:02 CDT
Upper trunk fat -- fat on the chest and back -- is associated with an increased risk of insulin resistance, a San Francisco VA Medical Center study found.
In insulin resistance, cells in the body become increasingly resistant to the action of insulin, a hormone that regulates blood glucose levels. The result is chronically high blood glucose, which has many adverse health effects, said principal investigator Dr. Carl Grunfeld.
The subjects were part of a national long-term longitudinal study of HIV infected people taking modern anti-retroviral therapy and HIV negative controls. The researchers found the association was equally strong in both HIV infected subjects and HIV negative subjects.
We knew about the insulin resistance risk associated with visceral fat -- located between and around the internal organs -- but no one had ever looked at the contribution of upper trunk fat, Grunfeld said in a statement.
Among the HIV infected subjects with the highest levels of upper trunk fat, 57 percent showed insulin resistance; of those, half lacked high visceral fat and among those who didn't have HIV, those with the highest levels of upper trunk fat, 61 percent were insulin resistant.
The findings are published in the Journal of Acquired Immune Deficiency Syndromes.
Source: United Press International
Related Articles
- Scientists Solve Mystery About Why HIV Patients Are More Susceptible To TB Infection
- Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics
- Sirtris Pharmaceuticals to Present at Keystone Symposia's Diabetes Mellitus, Insulin Action and Resistance Conference
- TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
- Orexigen(TM) Therapeutics Reports Contrave(TM) Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes
- OREXIGEN(TM) Therapeutics to Present Data on Contrave(TM) Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
- Theravance to Host Investor Conference Call Following Presentation at the Third International Symposium on Resistant Gram-Positive Infections
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin; 80 Percent of Diabetes Patients in Study Preferred Inhaled Insulin System to Mealtime Injections
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin
- Silent Upper Airway Resistance Syndrome*: Prevalence in a Mixed Military Population
 |
 |
User Comments (0)
RSS Feeds